Mark Donovan
- Cardiology and Cardiovascular Medicine top 1%
- Endocrinology, Diabetes and Metabolism top 2%
- Molecular Biology
- Surgery
- Oncology
- Co-authors
- Peter E. CarsonRobert S. McKelvieAgata PtaszynskaJohn J.V. McMurrayMichel KomajdaMichael R. ZileBarry M. MassieC Staiger
- Topics
- Diabetes Treatment and Management (9 papers)Metabolism, Diabetes, and Cancer (6 papers)Cardiovascular Function and Risk Factors (4 papers)
- Cited by
- Cardiology and Cardiovascular MedicineEndocrinology, Diabetes and MetabolismComplementary and alternative medicine
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Mark Donovan
18 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 77
- Cardiology and Cardiovascular Medicine 1.4k
- Endocrinology, Diabetes and Metabolism 722
- Molecular Biology 305
- Surgery 226
- Oncology 218
Countries citing papers authored by Mark Donovan
This map shows the geographic impact of Mark Donovan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Donovan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Donovan more than expected).
Fields of papers citing papers by Mark Donovan
This network shows the impact of papers produced by Mark Donovan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Donovan. The network helps show where Mark Donovan may publish in the future.
Co-authorship network of co-authors of Mark Donovan
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Donovan. A scholar is included among the top collaborators of Mark Donovan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Donovan. Mark Donovan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 15 | |
| 3 | 0 | |
| 4 | 53 | |
| 5 | 43 | |
| 6 | 46 | |
| 7 | 146 | |
| 8 | 14 | |
| 9 | 182 | |
| 10 | 0 | |
| 11 | Saxagliptin clinical trials: evaluation of CV risk | 2 |
| 12 | 25 | |
| 13 | Abstract 978: Cardiovascular Safety of Saxagliptin as Mono- or Add-on Therapy in Patients With Type 2 Diabetes | 2 |
| 14 | 49 | |
| 15 | 14 | |
| 16 | Irbesartan in Patients with Heart Failure and Preserved Ejection Fractionbreakdown → | 1362 |
| 17 | 1 | |
| 18 | 0 | |
| 19 | 13 | |
| 20 | 9 |
About Mark Donovan
Mark Donovan is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Internal Medicine, having authored 21 papers that have together received 2.1k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (9 papers), Metabolism, Diabetes, and Cancer (6 papers) and Cardiovascular Function and Risk Factors (4 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (1.4k citations), Endocrinology, Diabetes and Metabolism (722 citations) and Complementary and alternative medicine (79 citations). Mark Donovan has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Peter E. Carson, Robert S. McKelvie, Agata Ptaszynska, John J.V. McMurray, Michel Komajda, Michael R. Zile, Barry M. Massie, C Staiger, Susan Anderson and Erik Iverson. Their work appears in journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.